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Expression of the PML-retinoic acid receptor  (PML-RAR) fusion protein is the initiating genetic event
for acute promyelocytic leukemia (APL), but the molecular mechanisms responsible for disease initiation are
not yet clear. Several observations have suggested that early myeloid cells are uniquely susceptible to trans-
formation by PML-RAR. Recently, we have shown that the early myeloid-specific protease neutrophil elastase
is important for APL development in the mouse. To better understand the role of neutrophil elastase for the
pathogenesis of APL, we examined the consequences of PML-RAR expression in early myeloid cells with or
without neutrophil elastase. We found that high-level PML-RAR expression was associated with cellular
toxicity that was dependent on the expression of neutrophil elastase; a mutant form of PML-RAR that
resisted neutrophil elastase cleavage was not toxic. When PML-RAR was expressed at very low levels in the
early myeloid cells of mice, it induced myeloid expansion and delayed myeloid maturation; neutrophil elastase
was also required for these activities. The activities of PML-RAR in early myeloid cells are therefore strongly
influenced by the presence of neutrophil elastase. To assure physiologic relevance, PML-RAR functions
should be evaluated in neutrophil elastase-expressing early myeloid cells.
Almost all patients with acute promyelocytic leukemia
(APL) have transformed promyelocytes that carry the t(15;17)
(q22;q11.2) translocation, which generates the PML-retinoic
acid receptor  (PML-RAR) fusion gene product. The re-
quirement of PML-RAR for APL initiation was established
by expressing PML-RAR in the early myeloid compartment
of mice; some of these animals develop APL after a long latent
period. However, the mechanisms by which PML-RAR pre-
disposes early myeloid cells to eventual leukemic transforma-
tion are not yet completely understood.
The cellular compartment in which PML-RAR is ex-
pressed is important for its ability to cause leukemia. Trans-
genic and knock-in models expressing PML-RAR in early
myeloid cells (by using human cathepsin G [CG] [9, 10, 31] or
MRP8 [3] regulatory sequences) developed APL, but when
PML-RAR was expressed in late myeloid cells (by using
CD11b regulatory sequences), they did not (6). A retroviral
model directed PML-RAR expression to all early hemato-
poietic cells, but the only malignancy that developed was APL
(23). Together, these observations suggested that the early
myeloid compartment is uniquely susceptible to transforma-
tion as a result of PML-RAR expression; the interaction of
PML-RAR with one or more unique components of early
myeloid cells may therefore be relevant for APL pathogenesis
(32). We recently found that neutrophil elastase (NE), an early
myeloid-specific serine protease, is important for the develop-
ment of APL in mice (16); NE expression may therefore help
to define the susceptible hematopoietic cell for PML-RAR
actions.
PML-RAR has been proposed to act as a dominant nega-
tive inhibitor of endogenous PML (5) and RAR (13) func-
tion, causing resistance to apoptosis and a myeloid differ-
entiation block (8). However, data from two APL models
generated in our laboratory (using the same human PML-
RAR cDNA under the control of different CG regulatory
sequences) has argued against a simple dominant negative
model. A high-penetrance knock-in model expressed signifi-
cantly less PML-RAR mRNA than a low-penetrance trans-
genic model (31). A simple dominant negative model would
have predicted a direct relationship between expression level
and disease severity. Instead, our results suggested that the
selection of cells with a low level of PML-RAR expression
may be optimal for APL development. While these results
suggest that PML-RAR possesses gain-of-function properties
that are relevant for APL pathogenesis, they do not rule out a
contribution from dominant negative effects, since the level of
expression in APL-initiating cells is not yet known.
In this study, we have addressed some of these issues by
determining the consequences of direct PML-RAR expres-
sion in early myeloid cells that express or do not express neu-
trophil elastase. We found that PML-RAR-mediated disrup-
tion of PML oncogenic domains (PODs) is not dependent on
neutrophil elastase activity. However, high-level expression of
PML-RAR in early myeloid cells results in toxicity and cell
death that is neutrophil elastase dependent. Low-level expres-
sion of PML-RAR caused increased myeloid proliferation
and delayed maturation, which was also dependent on the
expression of neutrophil elastase. These findings suggest that
the functions of PML-RAR are strongly influenced by its
level of expression and the context of the cells in which it is
expressed. PML-RAR is expressed only in committed my-
eloid progenitors and transformed promyelocytes in human
APL patients (30), and these primary APL cells contain abun-
dant NE activity (16). Therefore, the most relevant actions of
* Corresponding author. Mailing address: Washington University,
Division of Oncology, 660 S. Euclid Ave., Campus Box 8007, St. Louis,
MO 63110-1093. Phone: (314) 362-9337. Fax: (314) 362-9333. E-mail:
tley@im.wustl.edu.
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PML-RAR occur at “physiologically appropriate” doses (de-
fined by regulatory sequences in the translocated locus) in APL
blasts that express NE. Study of the actions of PML-RAR
should therefore be performed with NE-expressing early my-
eloid cells to assure physiologic relevance.
MATERIALS AND METHODS
Mice. hCG-PML-RAR transgenic mice (9), mCGPML-RAR knock-in mice
(31), and mCG/PR NE/ mice (16) have been previously described. Wild-type
C3H  C57BL/6 F1 mice were obtained from Taconic. Animals expressing
PML-RAR in the context of NE deficiency were generated by intercrossing
mCGPR/ NE/ animals to obtain littermate progeny of all indicated geno-
types. For competitive repopulation experiments, recipient mice were Ly5.1-
expressing C57BL/6 congenic mice (B6.SJL-PtprcPep3bBoyJ; Jackson Labora-
tory, Bar Harbor, Maine). Donor mice were wild-type C57BL/6 congenic (Ly5.1/
Ly5.2 heterozygous) and NE-deficient C57BL/6 animals (Ly5.2).
Transient transfection and clonogenic assays. Cells (107) were electroporated
with 50 g of supercoiled plasmid DNA in RPMI medium and immediately
centrifuged at 300 g for 2 min. The cell pellet was incubated at 37°C for 15 min.
The resuspended cells were plated in RPMI medium containing 10% fetal calf
serum, L-glutamine, nonessential amino acids, sodium pyruvate, 50 M -mer-
captoethanol, and penicillin-streptomycin at 37°C in a humidified, 5% CO2
incubator. After 4 h, cells were washed with phosphate-buffered saline and
individual green fluorescent protein (GFP)-positive, 7-actinomycin D (7-AAD)-
negative cells were collected with a MoFlo (Cytomation, Inc., Fort Collins,
Colo.) high-speed cell sorter and plated directly into 96-well plates containing
growth medium. Fourteen days after sorting, plates were scored for the number
of colonies present. Data represent means and standard deviations from three
independent electroporations of each construct.
TUNEL staining. At 8 h after transfection, terminal deoxynucleotidyltrans-
ferase-mediated dUTP-biotin nick end labeling (TUNEL) staining was per-
formed with the TMR Red in situ death detection kit (Roche, Indianapolis, Ind.)
according to the manufacturer’s instructions. TUNEL positivity was scored in
each transfected population as the number of TUNEL-positive nuclei in one
microscopic field, with respect to the total number of nuclei present. Three fields
were scored for each of two separate electroporations; data represent means and
standard deviations.
In vitro myeloid differentiation. Eight- to 12-week-old C3H  C57Bl/6 F1,
C57BL/6  129/SvJ F1, hCG-PML-RAR, mCGPML-RAR, mCG/ NE/, or
mCG/PR NE/ mice were treated with 150 mg of 5-fluorouracil per kg intra-
peritoneally. Forty-eight hours later, marrow was harvested and plated in Dul-
becco’s modified Eagle’s medium containing 20% fetal calf serum, 100 ng of
murine stem cell factor (SCF) (R&D Systems, Minneapolis, Minn.) per ml, 6 ng
of murine interleukin-3 (R&D Systems) per ml, 50 ng of murine FLT3 ligand
(R&D Systems) per ml, and 10 ng of human thrombopoietin (PeproTech Inc.,
Rocky Hill, N.J.) per ml. After 72 h, mononuclear cells were purified by centrif-
ugation on Histopaque-1077 (Sigma, St. Louis, Mo.), and 100,000 Lineage Sca
light-density cells were collected on a MoFlo high-speed cell sorter. Those cells
were plated in Dulbecco’s modified Eagle’s medium with 20% fetal calf serum
containing 100 ng of SCF per ml and 100 ng of human granulocyte colony-
stimulating factor (G-CSF) (Amgen, Thousand Oaks, Calif.) per ml. Cells were
harvested daily for total RNA collected by using RNeasy (Qiagen, Valencia,
Calif.), manual cell counts, May-Grunwald-Giemsa staining (Sigma), and immu-
nofluorescence. Data are representative of those from three separate pools of
animals (n  5 per pool) of each genotype assayed in duplicate cultures in three
independent experiments (n  15 mice total per genotype).
Real-time quantitative reverse transcription-PCR (qRT-PCR). Real-time
PCR for PML-RAR and GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) mRNAs was performed as previously described (31), with the exception
that RNA was subjected to one round of linear amplification by the Siteman
Cancer Center Multiplexed Gene Analysis Core prior to PCR, as described
previously (http://pathology.wustl.edu/mgacore/protocols.htm), to compensate
for low RNA abundance. For CG and NE, RT-PCR was performed with primers
5	-AGTCCAGAAGGGCTGAGTGC-3	 (forward) and 5	-ATCAGGATGGCG
GATGGCTC-3	 (reverse) for CG and with primers 5	-CCTTCTCTGTGCAGC
GGATCTTC-3	 (forward) and 5	-ACATGGAGTTCTGTCACCCAC-3	 (re-
verse) for NE. Fluorescence 
CT values were used to calculate mRNA levels
relative to GAPDH mRNA; data represent means and standard deviations for
triplicate samples.
Immunofluorescence microscopy. Staining for human PML was performed by
fixing GFP fusion transfected cells on glass slides by incubation in methanol for
10 min at 20°C. Slides were blocked by incubation in Tris-buffered saline–
Tween 20 with 2% goat serum. The primary antibody was anti-human PML
(PG-M3; Santa Cruz Biotechnology, Santa Cruz, Calif.), and the secondary
antibody was Texas Red-conjugated anti-mouse immunoglobulin (Vector Labs,
Burlingame, Calif.), each diluted 1:200 in blocking buffer. Staining for murine
PML was performed with the Mouse on Mouse kit (Vector) with a monoclonal
antibody raised against murine PML (a generous gift of Scott Lowe, Cold Spring
Harbor, N.Y.). Fluorescein isothiocyanate-conjugated streptavidin was used for
fluorescence visualization. Cells were overlaid with fluorescence mounting me-
dium containing DAPI (4	,6	-diamidino-2-phenylindole) (Vector) for microscopy.
Western blotting. Western blot analysis for PML-RAR protein with an anti-
human RAR antibody (C-20; Santa Cruz) was performed as previously de-
scribed (16).
Neutrophil elastase protease activity. Quantitation of functional neutrophil
elastase activity by using a synthetic peptide substrate was performed as previ-
ously described (19). Cleavage activity in cell extracts was normalized to a
standard curve of purified human neutrophil elastase (Elastin Products, Owens-
ville, Mo.).
In vitro PML-RAR cleavage assay. Cleavage of in vitro-translated PML-
RAR by cell extracts was performed as previously described (16).
Competitive repopulation assay. NE/ (Ly5.2) and NE/ (Ly5.1/Ly5.2)
bone marrow samples were harvested from four congenic C57BL/6 age- and
sex-matched donor mice of each genotype. Total bone marrow cells (5  106)
were injected at ratios of 1:1, 9:1, and 1:9 (NE/ to NE/ cells) via the tail vein
into lethally irradiated (900 cGy) 8-week-old wild-type C57BL/6 (Ly5.1) mice.
Peripheral blood cells from transplant recipients (n  5 per group; n  15 total
recipients) were collected at 3 and 12 weeks posttransplant via the retroorbital
plexus, at which time fluorescent-antibody-mediated Ly5.1/Ly5.2 cell surface
staining and analysis of the relative contribution of each donor genotype to
various hematopoietic lineages were performed as previously described (27).
Antibodies and their appropriate isotype controls were obtained from BD Bio-
sciences PharMingen (San Diego, Calif.) and included CD45.1-fluorescein iso-
thiocyanate, CD45.2-PerCP, and phycoerythrin-conjugated B220, CD3ε, and Gr-1.
RESULTS
Transient PML-RAR overexpression is associated with
toxicity in early myeloid cell lines. To assess the effects of de
novo PML-RAR expression in cells that had not previously
been exposed to this protein, PML-RAR was transiently ex-
pressed in several myeloid and nonmyeloid human cell lines.
To define the transfected population, we created N-terminal
GFP fusions with PML-RAR or with the PML or RAR
portion of PML-RAR. Expression was detected by GFP flu-
orescence in transfected cells (Fig. 1A). Several independent
studies have found that GFP fusions to PML-RAR (22) and
to full-length PML (14, 25) or RAR (20) behave similarly to
the corresponding wild-type proteins for all functions assayed.
Here, in all cell lines tested, the transiently expressed fusion
proteins localized to the expected cellular compartments.
GFP-RAR was localized to the nucleus, GFP-PML was de-
tected in a small number of discrete subnuclear structures
(PODs), and GFP-PML-RAR was distributed in a micro-
speckled subnuclear pattern, characteristic of disrupted PODs.
Using an anti-human PML antibody that recognizes both the
transfected PML protein and endogenous PML, we found that
both GFP-PML and GFP-PML-RAR colocalized with en-
dogenous PML, either in intact PODs or in the microspeckled
distribution. U937 (myeloid) and K562 (nonmyeloid) cells
demonstrated a similar localization of all GFP fusion proteins.
Using flow cytometry, we consistently observed a high per-
centage of 7-AAD-positive cells in bulk populations of U937
myeloid cells transfected with GFP-PML-RAR, suggestive of
cell death (data not shown). To investigate the nature of this
death phenotype, cells were incubated in the presence of ter-
minal deoxynucleotidyl transferase, which labels free 3	-OH
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termini of DNA after single- or double-strand breakage
(TUNEL). U937 cells (and another early myeloid line, PLB-
985) demonstrated significantly increased TUNEL positivity
(and nuclear fragmentation) 8 h after electroporation with
GFP-PML-RAR versus GFP alone (5.4- 1.1-fold-increased
TUNEL positivity for PLB-985 and 7.0-  0.4-fold-increased
positivity for U937; P  0.01). HL60 cells (which are also
myeloid, but which express less NE activity [see Fig. 4]) and
nonmyeloid K562 and RAJI cells did not display a significant
difference in TUNEL positivity or nuclear fragmentation after
GFP-PML-RAR expression (Fig. 1B and C).
To directly examine the survival of single cells transiently
overexpressing PML-RAR, we developed a clonogenic assay
to assess cell death. Transfected cells were sorted on the basis
of GFP positivity 4 h after electroporation (Fig. 1D). At this
time point, we detected no difference in cell viability among
any of the constructs, as measured by 7-AAD, propidium io-
dide, or TUNEL staining (data not shown). Individual GFP-
FIG. 1. Cell death induced by transient expression of PML-RAR. (A) GFP fusion proteins were visualized by fluorescence microscopy 8 h
after transfection in U937 (top) or K562 (bottom) cells. Staining with an antibody recognizing human PML is also shown, as indicated (green, GFP;
red, PML; blue, DAPI; yellow, colocalization of GFP and PML signals). (B) TUNEL staining for U937 and K562 cells expressing the indicated
GFP fusion proteins. (C) TUNEL staining data for multiple cell lines expressing GFP or GFP-PML-RAR. Data are expressed as means and
standard deviations of the percentage of TUNEL-positive nuclei; significance was calculated by Student’s t test (, P  0.01). (D) Experimental
procedure for the clonogenic assay. The flow cytometry plot shows the GFP-positive, 7-AAD-negative sorted population. (E) Clonogenic data for
K562 and U937 cells transfected with the indicated GFP fusion constructs. The data are expressed as the number of positive wells relative to the
number of cells plated, normalized to the number of positive wells per cell plated for GFP-alone transfectants. Data are represented as means and
standard deviations for three independent electroporations; significance was calculated by Student’s t test (, P  0.01).
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positive cells were sorted, at dilutions of several cells per well,
into 96-well plates containing normal growth medium and were
cultured for 14 days, at which time the number of colonies was
scored relative to the number of cells plated. U937 cells that
experienced transient expression of GFP-PML-RAR had a
significantly reduced clonogenic potential relative to cells ex-
pressing GFP alone (78%  5% reduction; P  0.01). This
effect was specific for the GFP-PML-RAR cDNA, since GFP
fusions containing only the PML or RAR domain of PML-
RAR were no more toxic than GFP alone. K562 cells dis-
played no change in clonogenic potential after transfection
with GFP-PML-RAR (Fig. 1E).
PML-RAR expression in primary murine early myeloid
cells results in toxicity or proliferation, depending on the
transgene dose. In humans with APL, PML-RAR is normally
expressed in a committed myeloid progenitor compartment
and in transformed promyelocytes, not in the earliest stem or
progenitor cells (2, 30). We decided to study the de novo
expression of PML-RAR in early myeloid cells to better un-
derstand the relevant effects of PML-RAR in primary cells.
In our murine APL models, PML-RAR expression is driven
exclusively in early myeloid cells under the control of cathepsin
G regulatory sequences. Transgenic hCG-PML-RAR mice
express significantly more PML-RAR mRNA than the knock-
in mCGPML-RAR mouse. However, the mCGPML-RAR model
demonstrated greater than 90% penetrance of APL, while the
hCG-PML-RAR mouse demonstrated 15 to 20% penetrance
(31).
We hypothesized that early myeloid toxicity might be occur-
ring with the relatively high level of PML-RAR expression in
the hCG-PML-RAR mouse model. We therefore examined
bone marrow and spleen samples derived from wild-type 8-
to 12-week-old mice, or from the hCG-PML-RAR and
mCGPML-RAR strains, for evidence of cell death (determined
by cellular morphology and annexin V, 7-AAD, and TUNEL
staining). We did not observe increased numbers of apoptotic
cells in any sample (data not shown). However, apoptotic cells
can be difficult to detect in vivo, especially in tissues where
resident macrophages rapidly engulf dying cells (28). Further-
more, since promyelocytes represent only a very small fraction
of total bone marrow cells, a dying population of these cells
would be difficult to detect.
We therefore decided to examine the effects of PML-RAR
expression in primary cells in vitro, using a system where early
myeloid cell growth properties could be more easily de-
tected and quantified. We employed a modified version of a
G-CSF-dependent myeloid differentiation system developed
by McLemore et al. (21). Hematopoietic progenitors were
purified from murine bone marrow and treated for 7 days with
G-CSF and SCF, which induces a coordinate wave of myeloid
maturation (Fig. 2A). Real-time qRT-PCR of RNA derived
from wild-type cultures demonstrated that mRNA produced
by the primary granule protease cathepsin G and neutrophil
elastase genes peaked in abundance on day 2 of culture, coin-
cident with the peak of promyelocyte accumulation (Fig. 2B).
As expected, PML-RAR mRNA levels increased from day
0 to 2 in cells derived from hCG-PML-RAR mice (4.7- 
0.6-fold; P 0.01). PML-RAR from mCGPML-RAR cells was
much less abundant, and it was difficult to measure induction
since the measured mRNA levels were so close to that of
background (Fig. 2C).
Cell counts performed on these cultures over 7 days revealed
that the transgenic hCG-PML-RAR cells experienced a sig-
nificant loss of cell numbers on day 3 of culture, 1 day after the
induction of PML-RAR mRNA (the total cell number was
8.8%  4.1% of that of the wild type on day 3 in the experi-
ment shown). The major cell losses occurred in the blast-
promyelocyte compartment. Mature myeloid cells developed
normally, but their accumulation was delayed (Fig. 2D).
Knock-in mCGPML-RAR cells demonstrated consistently
higher cell numbers than wild-type cultures (2.61-  0.34-fold
over wild type from day 3 to 7), with the excess cells consisting
primarily of blasts and promyelocytes (Fig. 2D). Variability did
occur among experiments in terms of fold expansion and the
magnitude of the cell loss in hCG-PML-RAR cultures on
days 2 to 3, but several observations were consistent: hCG-
PML-RAR cells expanded at a lower rate than wild-type
cells, and mCGPML-RAR cells expanded more rapidly than
wild-type cells and displayed a more immature phenotype.
Cells were examined on days 0, 2, and 7 for endogenous
mouse PML localization as a functional assay for the presence
of PML-RAR protein; cells expressing PML-RAR should
display a microspeckled distribution of endogenous PML (5).
Nearly all progenitor cells displayed normal POD structures on
day 0 of culture, suggesting that these early progenitors had
not yet reached the stage of transgene activation (Fig. 2E). On
day 2, the majority of cells in both hCG-PML-RAR and
mCGPML-RAR cultures displayed a microspeckled distribution
of PML. By day 7, most hCG-PML-RAR cells displayed a
normal POD-like distribution of PML, although rare cells still
demonstrated a microspeckled pattern. In contrast, the major-
ity of mCGPML-RAR cells continued to display a microspeck-
led PML distribution from day 3 to 7.
Myeloid cell lines containing full-length PML-RAR ex-
press no neutrophil elastase activity. Two frequently used cell
line models of APL are U937-PR9, a U937 subclone carrying
FIG. 2. In vitro granulocytic differentiation of myeloid progenitors from two murine models of APL. (A) Manual myeloid differential counts
from wild-type cultures over 7 days. Black, myeloblasts and undifferentiated progenitors; red, promyelocytes; green, myelocytes and metamyelo-
cytes; blue, bands and mature neutrophils. (B) Real-time qRT-PCR on wild-type cells for the primary granule proteases cathepsin G and neutrophil
elastase. Data are expressed as mean mRNA fold change for each gene relative to GAPDH mRNA abundance and standard deviation, each
performed in triplicate. (C) Real-time qRT-PCR on cells from wild-type, hCG-PML-RAR, and mCGPML-RAR cells at days 0 and 2 of culture.
Data are expressed as in panel B. The dotted line represents the maximum background signal from wild-type cultures. Significance was calculated
by Student’s t test (, P  0.01). (D) (Left) Mean cell numbers and standard deviations over time in culture; data represent those for one of three
independent experiments, each plated in duplicate (, P  0.05; ,  P  0.01 [for hCG-PML-RAR or mCGPML-RAR versus wild-type
cultures]). (Right) Manual differentials were scored on each day in culture by counting 100 May-Grunwald-Giemsa-stained cells. Absolute numbers
of the indicated myeloid subsets were calculated by multiplying the fraction of each by the total number of cells. (E) Immunofluorescence
microscopy with an antibody recognizing mouse PML.
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a zinc-inducible PML-RAR cDNA (8), and NB4, a cell line
cloned from an APL patient with t(15;17) (17). Induced PR9
cells and NB4 cells express abundant full-length bcr-1-derived
PML-RAR protein, as determined by Western blotting
against RAR (Fig. 3A). The ability of these cells to express
full-length PML-RAR is paradoxical, in light of the demon-
strated toxicity of PML-RAR in unmanipulated early myeloid
cells. We previously showed that PML-RAR is cleaved by NE
in early myeloid cells and cell lines (including U937) (16); we
therefore measured the activity of NE in these cell lines by
using a specific, peptide-based cleavage assay. PR9 and NB4
cells contained essentially no measurable NE activity (Fig. 3B).
This data are supported by a recent report by Park et al. (26),
who found that steady-state levels of NE mRNA were 4,000-
fold lower in U937-PR9 cells than in U937 cells.
We next examined the cleavage of PML-RAR by using
extracts from these cell lines. While extracts from U937 cells
efficiently cleaved PML-RAR (Fig. 3C, lane 5), extracts from
K562 (lane 3) and PR9 (lane 7) cells did not. Mutations of the
dominant NE cleavage sites of PML-RAR (16) resulted in a
near-complete loss of cleavage by U937 extracts (Fig. 3C, lane
6). We also correlated neutrophil elastase activity and the
sensitivity of human hematopoietic cells to PML-RAR-in-
duced toxicity (Fig. 1C). U937 and PLB-985 cells contained the
highest levels of NE activity and were the most susceptible;
K562, RAJI, and HL60 cells contained lower levels of NE
activity and were not killed by PML-RAR (Fig. 3D).
PML-RAR toxicity in early myeloid cell lines is associated
with its cleavage by neutrophil elastase. In light of the findings
described above, we reasoned that the toxicity of PML-RAR
in early myeloid cells might be dependent on its cleavage by
NE. We found that the toxicity of PML-RAR in U937 cells
was lost when the two primary NE cleavage sites (V420 and
V432) were mutated to arginines (2VR) (Fig. 4A). The 2VR
PML-RAR protein was expressed at levels comparable to
those of wild-type PML-RAR, and it caused a similar mi-
crospeckled nuclear distribution of PML (as expected, since
NE is not required for POD disruption [Fig. 1 and data not
shown]). Cotransfection and expression of either the N-termi-
nal or C-terminal dominant cleavage fragments alone (or in
combination) did not result in any loss of clonogenic potential
compared to GFP alone (Fig. 4A), suggesting that expression
of the intact protein, followed by NE-dependent cleavage, is
required to cause toxicity. This observation is in agreement
with immunofluorescence localization studies of the cleaved
fragments of PML-RAR, where we observed differential lo-
calization of the fragments depending on whether they were
cleaved in the cell or expressed exogenously as cleavage frag-
ments (16). Finally, we transiently expressed PML-RAR in
U937-PR9 cells, which possess minimal NE activity compared
with parental U937 cells. Overexpression of wild-type PML-
RAR induced no measurable toxicity in these cells, as pre-
dicted (Fig. 4B).
Neutrophil elastase deficiency does not alter the repopulat-
ing activity of hematopoietic progenitor cells. We previously
demonstrated that in the absence of NE, the penetrance of
APL in mCGPML-RAR mice is reduced from 100 to 45% at 300
days (16). One potential explanation for those results is that
NE deficiency alters the size or differentiation capacity of the
“transformable pool” of myeloid progenitors. To address this
issue, we performed a competitive repopulation assay to assess
potentially subtle defects in NE-deficient myeloid progenitor
cells. NE/ and NE/ bone marrow cells were combined at
various ratios to reconstitute the hematopoietic systems of
congenic, lethally irradiated, wild-type recipient mice. Ly5 cell
FIG. 3. Neutrophil elastase levels and PML-RAR protein expres-
sion in cell line models of APL. (A) Western blotting with a human
RAR-specific antibody for U937 cells, untreated U937-PR9 cells,
U937-PR9 cells induced with 100 M ZnSO4 for 16 h, and NB4 cells.
(B) Quantitation of NE protease activity in the indicated cell lines. The
data are shown as the means and standard deviations from two exper-
iments, each performed in triplicate, of nanograms of equivalent ac-
tivity per microgram of extract, normalized to a dilution curve of
purified human NE (, P  0.0001). (C) Western blotting against
RAR for the cleavage products of in vitro-translated wild-type PML-
RAR (wt) or the double-cleavage-site mutant of PML-RAR (2VR).
In vitro-translated PML-RAR was incubated with 10 g of the indi-
cated cell extracts for 15 min at 37°C. (D) Quantitation of NE protease
activity in the indicated cell lines. The data are expressed as in panel B.
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surface markers differed between the two donors and the re-
cipient animals, allowing the measurement of the relative con-
tribution of each population to multilineage hematopoiesis.
NE/ and NE/ bone marrow cells reconstituted the B-cell,
T-cell, and myeloid lineages with equal efficiency at 3 and 12
weeks posttransplant (Fig. 5). These data suggest that NE
deficiency per se does not cause a cell autonomous growth or
differentiation defect in hematopoietic progenitors.
Neutrophil elastase influences the proliferation and differ-
entiation of primary early myeloid cells expressing low levels
of PML-RAR. We decided to determine whether NE in-
fluences the phenotype of early myeloid cells expressing
low levels of PML-RAR. We therefore performed in vitro
myeloid differentiation of cells from wild-type (mCG/
NE/) mCGPML-RAR mice, NE-deficient (mCG/ NE/)
mCGPML-RAR mice, or knock-in mCGPML-RAR mice with
(mCGPR/ NE/) or without (mCGPR/ NE/) NE. First, it
was important to determine whether NE deficiency alone al-
ters myeloid development in our in vitro granulocytic differ-
entiation assay. In agreement with the results of the com-
petitive repopulation assay described above, we observed no
measurable differences in the growth of wild-type versus NE-
FIG. 4. Relationship between PML-RAR toxicity and its cleavage
by neutrophil elastase. (A) Clonogenic data for U937 cells transfected
with the indicated GFP fusion cDNAs. WT, wild-type PML-RAR;
2VR,  PML-RAR containing the double NE cleavage-site mutant;
N-term and C-term, predicted N-terminal and C-terminal NE cleavage
products of PML-RAR, respectively; NC-term, cotransfection of
both cleavage fragments. The data are represented as in Fig. 1D (,
P  0.01). (B) Clonogenic data for U937 or U937-PR9 cells trans-
fected with GFP or GFP-PML-RAR. The data are represented as in
Fig. 1D (, P  0.01).
FIG. 5. Competitive repopulation assay with NE/ and NE/
hematopoietic progenitor cells. The percentages of NE/ cells in
various peripheral blood hematopoietic subsets at 3 weeks (A) and 12
weeks (B) after bone marrow transplantation are shown. The expected
percentage of NE/ cells, based on the transplanted input ratio, is
50% (for a 1:1 transplant, NE//NE/), 90% (9:1, NE//NE/),
or 10% (1:9, NE//NE/). The percentages of NE/ cells of donor
origin in total peripheral blood leukocytes, or within the B220, CD3,
or Gr-1 subset, are shown. The data are expressed as means and
standard deviations for n  5 mice at each ratio.
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deficient myeloid progenitors in vitro (Fig. 6). Together, these
data suggest that a cell-intrinsic interaction between PML-
RAR and NE or a combined effect of their expression in early
myeloid cells is important for APL in vivo. To test this hypoth-
esis, we compared the expansion and development of myeloid
progenitors derived from mCGPR/ mice with or without NE.
The myeloproliferative phenotype and immaturity observed
with mCGPR/-derived progenitors was not detected in the
NE-deficient background (Fig. 6).
DISCUSSION
In this report, we have shown that several of the measurable
activities of PML-RAR in early myeloid cells depend on
neutrophil elastase, a myeloid-specific serine protease that is
maximally expressed in promyelocytes. NE is not important for
the ability of PML-RAR to disrupt PODs, since this activity
occurs in K562 cells, which do not express NE. When ex-
pressed at high levels, PML-RAR is toxic to human myeloid
cell lines that express NE. Conversely, two commonly used
myeloid cell lines (NB4 and U937-PR9) that express high lev-
els of full-length PML-RAR protein completely lack NE ac-
tivity. Primary murine bone marrow progenitors that expressed
relatively high levels of PML-RAR in promyelocytes demon-
strated significant cell loss at the peak of expression. However,
with low-level expression of PML-RAR in primary early my-
eloid cells, the cells proliferated more rapidly and differenti-
ated with delayed kinetics. Both of these effects were NE
dependent, although NE deficiency alone did not affect my-
eloid development. In sum, the data presented here clearly
show that NE is relevant for many of the activities of PML-
RAR in early myeloid cells, and this may help to explain why
promyelocytes are uniquely susceptible to the transforming
activity of PML-RAR.
The t(15;17) translocation is not associated with any malig-
nancy other than APL. Mouse models have shown that PML-
RAR must be targeted to the early myeloid compartment to
initiate APL and have suggested that other hematopoietic cells
are not susceptible to transformation by this fusion protein.
Promyelocytes are the cells that accumulate in APL, suggesting
that a unique interaction occurs between the t(15;17) fusion
protein(s) and the promyelocytic environment. We previously
showed that neutrophil elastase was important (but not re-
quired) for the development of PML-RAR-initiated APL in
the mouse. In this report, we have shown that NE is important
for several of the measurable effects of PML-RAR in early
myeloid cells, including toxicity (at high doses) and excessive
proliferation and altered development (at low doses). How-
ever, it is also clear that NE-deficient mice can develop APL
that is phenotypically identical to APL in wild-type animals;
the main differences are that latency is prolonged and pen-
etrance is reduced in the NE-deficient mice. These data
strongly suggest that other promyelocyte-specific factors may
also be involved in APL pathogenesis.
How does neutrophil elastase affect the activities of PML-
RAR? The answer is not yet clear. We previously showed that
PML-RAR is cleaved by NE in early myeloid cells and iden-
tified the dominant cleavage sites within the carboxy-terminal
domain of PML in the fusion protein. However, alternative
minor cleavage sites also exist, and with prolonged exposure to
NE, proteolysis progresses to yield additional cleavage frag-
ments and ultimate destruction of the protein. Alternative
FIG. 6. In vitro differentiation of myeloid progenitors from mCGPML-RAR cells with or without neutrophil elastase. (Left) Mean cell numbers
and standard deviations over time in culture. Data represent cultures of bone marrow from one of two independent experiments with five mice
of each genotype, each plated in duplicate (, P  0.05; , P  0.01 [for mCG/PR NE/ versus wild-type cultures]). Cell counts are presented
on a linear scale because no toxicity occurred in this experiment, unlike for Fig. 2, where a log scale was used to show cell loss on days 2 to 3 and
expansion at later time points. (Right) Manual differentials were scored on each day in culture by counting 100 May-Grunwald-Giemsa-stained
cells. Absolute numbers of the indicated myeloid subsets were calculated by multiplying the fraction of each by the total number of cells.
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early myeloid-specific proteases (cathepsin G and proteinase
3) also have the ability to cleave PML-RAR in vitro, but with
reduced efficiency and in different sites (16). Thus, it is entirely
possible that NE may not create PML-RAR fragments with
novel functions but may instead initiate a generalized turnover
mechanism for PML-RAR by first cleaving the two promi-
nent sites in the PML domain. Accordingly, neither of the large
NE cleavage products of PML-RAR was properly trafficked
in U937 cells, and neither caused toxicity on its own (Fig. 4)
(16).
Is it possible that cleavage of PML-RAR is simply a marker
for NE activity and that the effects of NE on myeloid growth
and development are not mediated by a direct interaction with
the PML-RAR protein itself? This line of reasoning has been
suggested by the study of severe congenital neutropenia, a
syndrome associated with heterozygous mutations the Ela2
gene (encoding NE); these mutant NE molecules may contrib-
ute to the altered myeloid development and excess AML that
is seen in these patients (11, 18). However, two lines of evi-
dence suggest that this does not explain our results. First, NE
deficiency per se does not appear to alter myeloid development
in vitro or in vivo. Second, the NE-resistant form of PML-
RAR has a phenotype: it does not cause toxicity in U937 cells
that express NE. Regardless of the precise molecular mecha-
nism, our findings strongly suggest that NE directly alters
PML-RAR functions and that it does not influence APL
development by altering the myeloid progenitor pool. How-
ever, to directly assess the importance of NE-induced PML-
RAR cleavage for leukemogenesis, it will be important to
express the NE-resistant form of PML-RAR in the early
myeloid cells of transgenic mice. This experiment is in prog-
ress, but it will require 2 years to complete.
PML-RAR-induced toxicity has previously been described.
In an attempt to generate stable, PML-RAR-expressing sub-
clones of hematopoietic cell lines by using a retroviral vector,
Grignani et al. (8) found that certain cell lines were “permis-
sive” for PML-RAR expression. Interestingly, U937 cells
were one of the cell types that could stably express PML-
RAR, but only a fraction of the total stable integrants ex-
pressed detectable amounts of protein. In several “nonpermis-
sive” fibroblast cell lines, PML-RAR expressed under the
control of the retroviral vector induced toxicity and apoptotic
cell death (7). One study, using a human fibroblast cell line,
suggested that PML-RAR could induce toxicity by causing
the unfolded protein response and endoplasmic reticulum
stress (15). Finally, when PML-RAR was expressed in trans-
genic mice under the control of actin regulatory sequences, no
transgene-positive mice were born, suggesting that high levels
of PML-RAR in nonhematopoietic tissues may be toxic and
incompatible with embryonic development (10). Similarly,
when transgenic mice carrying a PLZF-RAR cDNA under
control of the strong, ubiquitous cytomegalovirus or simian
virus 40 promoter were created, no expression of the transgene
could be detected, nor did any of the mice develop myelopro-
liferation or leukemia (4). However, since many of these stud-
ies were performed by expressing PML-RAR in nonhemato-
poietic cells that do not express NE, it is hard to assess their
physiologic relevance, in light of the data presented here.
In our transgenic mouse model of APL, a relatively high
level of PML-RAR expression at the promyelocyte stage is
associated with cellular loss; these mice have a relatively low
penetrance of APL. In an attempt to explain these findings, we
have developed the model shown in Fig. 7. The majority of
early myeloid cells in the high-expressing hCG-PML-RAR
transgenic model may cross a “toxic threshold” of PML-RAR
expression, resulting in their deletion and removal from the
pool of transformable cells (Fig. 7). In contrast, in the low-
expression mCGPML-RAR knock-in model, many fewer cells
would express toxic amounts of PML-RAR. At these low
doses, PML-RAR may expand the pool of myeloid progeni-
tors, increasing the number of cells that could potentially ac-
quire the “hits” required for progression to acute leukemia.
How could NE play a role in the low-dose, proliferative phe-
notype? It is possible that NE and CG are both expressed at
very low levels before they are fully activated at the promye-
locyte stage (Fig. 7); recent studies have indeed suggested that
“late” myeloid genes can be expressed at low levels in hema-
topoietic stem and myeloid progenitor cells (12, 24, 33). In
early myeloid progenitors, our data suggest that low levels of
NE and PML-RAR may cooperate to cause the proliferation
and altered differentiation detected in the knock-in model.
The NB4 cell line and induced U937-PR9 cells contain
abundant full-length PML-RAR protein, and they can grow
in culture, even though PML-RAR is known to be toxic to
FIG. 7. Model for the roles of PML-RAR dose and NE expres-
sion in APL penetrance. At the time when differentiating myeloid cells
reach the stage of peak cathepsin G transgene activation (green cells),
the population experiences a normal (stochastic) distribution of PML-
RAR expression on a per-cell basis. Some earlier progenitor cells
may also express very low levels of cathepsin G (i.e., PML-RAR) that
may actually increase progenitor proliferation (see Discussion). Since
the cathepsin G and neutrophil elastase genes are regulated in a
similar fashion, NE expression should also occur in cells expressing
PML-RAR. The low-expressing mCGPML-RAR model is represented
by the red histogram, and the high-expressing hCG-PML-RAR trans-
genic model is represented by the blue histogram. In this model, cells
expressing PML-RAR above a threshold level (gray box) experience
toxicity, while the low expressers survive and expand to support the
myeloid compartment. More cells in the mCGPML-RAR model fall
within the survival window. Since the transformable progenitor pool is
larger in these mice, they may be more likely to acquire the necessary
adaptations or changes that predispose early myeloid cells to leukemic
transformation, which is detected as a higher penetrance of disease.
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early myeloid cells. This paradox may be explained by the fact
that both of these cell lines completely lack NE activity, which
we have shown to be necessary for PML-RAR-induced tox-
icity. This suggests that these two cell lines may have lost NE
expression as a required adaptation for the growth of PML-
RAR-expressing cells in vitro. In support of this hypothesis,
preliminary data from our lab have suggested that murine APL
blasts lose NE activity when they are established as long-term
in vitro cultures (A. A. Lane and T. J. Ley, unpublished data).
Are NB4 cells true “APL blasts,” or are they in fact a selected,
adapted population of cells that express high levels of PML-
RAR? NB4 cells are cytogenetically complex, with a hypo-
tetraploid karyotype and multiple chromosomal alterations,
and they have very few (if any) azurophil granules and no NE
(reference 17 and data not shown). In contrast, the majority of
primary human APL blasts demonstrate t(15;17) as their sole
cytogenetic abnormality, they contain abundant azurophil
granules, and they express very large amounts of NE (1, 16,
29). Together, these observations imply that NB4 and PR9
cells represent a strongly selected, adapted subpopulation of
early myeloid cells that do not contain many of the key features
of primary APL blasts. We are currently studying the adapta-
tions that occur in early myeloid cells that allow for PML-
RAR expression, to better understand their biological rele-
vance in vitro and, potentially, in vivo.
Taken together, the data reported here show that the inter-
action of PML-RAR with neutrophil elastase can cause a
toxic insult to early myeloid cells, or it can confer a prolifera-
tive advantage, depending on the dose of PML-RAR that is
expressed. These data underscore the importance of under-
standing oncogene expression levels, and the cellular compart-
ments in which they act, as additional models of cancer are
created and analyzed in mice. These observations have sug-
gested a mechanism that can explain the paradoxical features
of several mouse models of APL, and they highlight the im-
portance of studying PML-RAR functions in a physiologic
context (i.e., early myeloid cells that contain NE activity).
These findings also implicate NE as a potential therapeutic
target in APL. We do not yet know whether NE activity is
important only at the initiation stage of APL or whether it is
also important for the growth properties of fully transformed
APL cells. Regardless, human and murine APL cells contain
abundant NE activity; assessing the effects of NE inhibition in
primary APL cells is a logical next step and is under investi-
gation.
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